Press releases
KANE BIOTECH ANNOUNCES AMENDMENT TO PRIVATE PLACEMENT OFFERING
WINNIPEG, Manitoba (May 10, 2006) - Kane Biotech Inc. (TSX-V:KNE), (the "Company"), a leading biofilm company, announces today today announced an amendment to the terms of its private placement offering (the "Offering") announced on April 20, 2006. The Company is amending the Offering to sell up to 2,181,818 units ("Units") at a price of $0.55 per Unit for gross proceeds of up to $1,200,000. Each Unit shall be comprised of one Share and one half of one Share purchase warrant (a "Warrant"). Each whole Warrant shall entitle the holder thereof to purchase one Share at a price of $0.70 per Share for a period of 18 months from the date of issuance of the Warrant. The previously announced details of the Offering were to sell up to 2,000,000 common shares ("Shares") at a price of $0.60 per Share for gross proceeds of up to $1,200,000. All other terms of the Offering remain the same.
The Offering is subject to receipt of all necessary approvals, including the approval of the TSX Venture Exchange.
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the development of products to prevent and disperse bacterial biofilms. Biofilms develop when bacteria, and other microorganisms, form a protective matrix that acts as a shield against attack. When in a biofilm, bacteria become highly resistant to antibiotics, high temperatures and host immune responses. This resiliency contributes to human health problems such as recurrent urinary tract infections, medical device associated infections and tooth decay.
For more information, please contact:
Michael Coutts
Director, Business Development
Kane Biotech Inc.
204-477-7597 phone
204-453-1314 fax
info@kanebiotech.com
www.kanebiotech.com
Certain information contained in this press release may be forward-looking and is subject to risks and uncertainties. Although the Company believes that the expectations contained herein are reasonable, it can give no assurances such forward-looking statements will prove correct. Information is provided from sources deemed to be reliable.
The TSX Venture Exchange has neither approved nor disapproved the contents of this press release.




